Public Health Agency of Canada

In order to develop technical guidance to support F/P/T public health authorities and front-line clinicians in health care settings responding to the novel coronavirus causing COVID-19, a number of assumptions were taken to develop interim guidance documents.

This document outlines the recommended goals, objectives, and activities for surveillance of human infection with COVID-19 in Canada. These guidelines are based on current available scientific evidence and expert opinion and are subject to change as new information becomes available.

Research: Gap analyses to assess Canadian readiness for respiratory syncytial virus vaccines: Report from an expert retreat. Published on Canada Communicable Disease Report (CCDR), volume 46-4, April 2, 2020.

Organizations, community health workers and volunteers play an important role in helping prevent the spread of COVID-19 among those who experience homelessness. It is important that these service providers plan ahead and take precautions in their environments/workplaces, based on public health...

Canadian public health guidance related to COVID-19 has been changing as the evidence base and our understanding of COVID-19 is rapidly evolving. We are continually looking at the evidence as it is being produced and working with our partners across the country and around the world to learn more.

This document provides recommendations and guidance for re-opening approaches that can be tailored to jurisdictions across the country. It draws on and supports the First Ministers Statement on a shared public health approach to support restarting the economy, and elaborates further advice on...

Workplaces/businesses can implement key measures to limit the spread of the virus in their settings. Workplaces/ businesses are heterogeneous; therefore, the Public Health Agency of Canada recommends that employers and business owners conduct a risk assessment to determine the most appropriate...

While diseases can make anyone sick, some Canadians are more at risk of developing severe complications from an illness due to underlying medical conditions and age. If you are at risk for complications, you can take action to reduce your risk of getting sick from COVID-19.

The purpose of this document is to provide planning guidance for the delivery of health care in Canada during the COVID-19 pandemic, which is expected to result in a prolonged period of increased demand on the health care system.

The Public Health Agency of Canada, in collaboration with Canadian public health and infection prevention and control (IPC) experts and the Funeral Services Association of Canada, has developed this guidance on public health measures for the management of mass fatalities from COVID-19. The...

The Public Health Agency of Canada, in collaboration with Canadian public health, infection prevention and control (IPC) experts, and the Funeral Service Association of Canada has developed this document to provide guidance on IPC and public health measures in relation to death care services in...

The Public Health Agency of Canada (PHAC) develops evidence-informed infection prevention and control guidelines and recommendations to complement provincial and territorial public health efforts in monitoring, preventing, and controlling healthcare-associated infections. The intended purpose of...

The Public Health Agency of Canada released evidence-informed guidelines to help residents, seniors and health care workers in long-term care homes remain safe and healthy. The "Infection Prevention and Control for COVID-19: Interim Guidance for Long-Term Care Homes" provides recommendations that...

Emergency Situation Facing Canadians in Light of the COVID-19 Pandemic

HESA February 26 - President of PHAC appeared with the Vice-President of Logistics and Operations

This primer is intended to support health care providers in better understanding and addressing COVID-19 vaccine hesitancy, in their practice and beyond.

COVID-19 vaccine ingredients in the Pfizer-BioNTech, Moderna and AstraZeneca vaccines.

We present the most up-to-date data on SARS-CoV-2 antibody timelines, including the longevity of antibodies, and the production and detection of neutralizing antibodies and provide practical guidance for clinical microbiology laboratories to both verify commercial serology assays and choose...

Simple mathematical modelling approaches to assessing the transmission risk of SARS-CoV-2 at gatherings

Serum antibody response in COVID-19-recovered patients who retested positive